Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: J Hypertens. 2017 Jul;35(7):1381–1389. doi: 10.1097/HJH.0000000000001319

Table 1.

Genotypic and phenotypic characteristics for initial examinationa in the eight cohorts analyzed.

Cohort Chip Version # analyzed % Female Mean Age (SD) Mean BMI (SD) Mean SBP (SD) Mean DBP (SD) % on anti-hypertensive medication
AADM v1.1 2070 57 45.55 (16.02) 25.96 (5.821) 132.69 (22.65) 81.01 (14.19) 28
ARIC v1.0/v1.1 3095 63 53.61 (5.80) 29.72 (6.26) 128.63 (21.00) 79.65 (12.15) 41
CARDIA v1.0 1534 58 31.45 (3.80) 28.24 (6.82) 111.33 (13.01) 70.92 (10.97) 3.2
GenNet v1.1 782 60 40.42 (11.45) 30.25 (8.12) 127.09 (20.20) 77.70 (13.60) 100
GENOA v1.1 1373 69 56.67 (10.66) 31.02 (6.57) 131.69 (23.51) 70.96 (11.53) 100
HUFS v1.1 1784 61 43.41 (14.44) 30.69 (8.672) 127.38 (20.99) 80.18 (12.87) 27
HyperGEN v1.1 1798 65 48.56 (12.84) 32.09 (7.61) 130.10 (22.31) 74.67 (12.00) 100
LUC v1.1 2688 71 48.66 (11.72) 26.12 (6.17) 146.09 (29.98) 91.92 (18.64) 39

BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; SD, standard deviation

a

As this only illustrates the first visit or phase, there are many individuals in subsequent examinations that are included in these analyses but not in this table; the complete information may be found in Table S1.